This traditional demographic profile of Type 2 diabetes (T2DM) has dramatically altered over the last couple of decades; the sharp rise in levels of obesity and sedentary lifestyles witnessed in younger age groups in developed countries has resulted in up to a 10-fold increase in the prevalence of T2DM in younger adults and youth. T2DM in the young is associated with a particularly deleterious phenotype, including a high risk of early cardiovascular disease and impaired cardiac function.
This novel trial aims to assess whether Liraglutide,a GLP-1 analogue, leads to improved left ventricular diastolic function in younger adults with T2DM compared to the clinical relevant active comparator Sitagliptin, a DPP-4 inhibitor. A Prospective, Open-label, Randomised, Blinded End-point (PROBE) active-comparator trial will be employed with 90 individuals randomised (1:1) to receive a maintenance dose of 1.8 mg/daily Liraglutide or 100mg/daily Sitagliptin. The primary outcome will be peak end diastolic strain rate, measured by gold-standard tagged cardiac MRI at baseline and 26-weeks. Secondary outcomes include a host of biochemical, anthropometric and lifestyle variables. The study is match funded by Novo Nordisk as part of an investigator initiated grant.
For recruitment details see LYDIA Study Page on our sister website: www.leicestershirediabetes.org.uk/891.html